Skip to Content

Invokana Approval History

  • FDA approved: Yes (First approved March 29th, 2013)
  • Brand name: Invokana
  • Generic name: canagliflozin
  • Dosage form: Tablets
  • Company: Janssen Research & Development, LLC
  • Treatment for: Diabetes, Type 2

Invokana (canagliflozin) is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

Development History and FDA Approval Process for Invokana

Mar 29, 2013Approval FDA Approves Invokana to Treat Type 2 Diabetes
Jan 11, 2013FDA Advisory Committee Recommends Approval of Canagliflozin for Treatment of Adults with Type 2 Diabetes
May 31, 2012Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.